Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Observational study of cilvelestat sodium for ARDS
ChiCTR2400084638Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sivelestat in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Tianjin Medical University General Hospital. Primary endpoint: Oxygenation index (PaO2/FiO2) and SpO2/FiO2 on day 7. Planned start May 2024; status: not yet recruiting.
02
Drugs
sivelestat
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2400084638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084638.